Comparative Outcomes of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Introduction to Biologics

• The American Academy of Allergy, Asthma, and Immunology recommends dupilumab and omalizumab as the most beneficial biologics for chronic rhinosinusitis with nasal polyps (CRSwNP), with dupilumab showing superior effects on disease-specific quality of life and nasal symptoms 1, 2

FDA-Approved Biologics for CRSwNP

• The FDA-approved biologics for CRSwNP treatment include dupilumab (anti-IL-4Rα), omalizumab (anti-IgE), and mepolizumab (anti-IL-5), with specific dosing regimens for each 1, 2

Comparative Efficacy on Disease-Specific Quality of Life

• Dupilumab achieves the largest improvement in SNOT-22 scores, with a mean difference of -19.91 points, exceeding the minimally important difference by more than twofold 2
• Omalizumab produces a mean difference of -16.09 points in SNOT-22 scores 2

Nasal Symptom Score Improvements

• Dupilumab leads in nasal symptom score improvements, with a mean difference of -3.25 points, followed by omalizumab (-2.09 points) and mepolizumab (-1.82 points) 2

Objective Measures

• Dupilumab consistently demonstrates superior nasal polyp reduction across randomized controlled trials and real-world studies 3
• Dupilumab produces significant improvements in CT scan opacification scores at both 24 and 52 weeks 3
• Dupilumab demonstrates significant improvement in smell identification testing, with benefits observed as early as 16 weeks and sustained through 52 weeks 3

Safety Profile Comparison

• All approved biologics demonstrate similar low rates of adverse events leading to discontinuation, with no significant difference from placebo in overall adverse event rates, though certainty of evidence is low to very low 2

Clinical Context for Biologic Selection

• Patients with high baseline disease burden who have failed intranasal corticosteroids for at least 4 weeks should preferentially receive dupilumab or omalizumab based on superior efficacy across multiple patient-important outcomes 1, 2
• Comorbid atopic dermatitis provides dual indication for dupilumab 4
• Patients with elevated IgE levels and comorbid allergic asthma represent the ideal population for omalizumab 1, 2

Treatment Sequencing Algorithm

• For patients with CRSwNP who have used intranasal corticosteroids for at least 4 weeks without adequate symptom control, a treatment sequencing algorithm is recommended, with dupilumab as first-line for high disease burden and comorbid atopic dermatitis, and omalizumab as first-line for high disease burden and elevated IgE and allergic asthma 1, 2, 4

Common Pitfalls

• Avoid initiating biologics in patients who have not tried intranasal corticosteroids for at least 4 weeks, as this represents the conditional nature of the guideline recommendation 1, 2
• Do not assume tezepelumab has equivalent evidence to dupilumab, omalizumab, or mepolizumab for CRSwNP 5

Comparative Efficacy and Safety of Biologics for CRSwNP

Hierarchy of Efficacy

• Dupilumab shows superior nasal polyp score reduction with a mean decrease of -1.79 points at 4-6 months, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 guidelines 6
• Dupilumab demonstrates the most robust improvement in UPSIT scores with a mean difference of 10.83 points at 4-6 months, in patients with CRSwNP, as reported in Rhinology 2020 6
• Dupilumab produces significant improvements in Lund-Mackay scores with a standardized mean difference of -1.50 at 4-6 months, in patients with CRSwNP, as published in Rhinology 2020 6
• These improvements in Lund-Mackay scores are sustained through 52 weeks of treatment, in patients with CRSwNP, according to Rhinology 2020 7

Safety Profile Comparison

• Dupilumab is associated with conjunctivitis in atopic dermatitis trials, but not observed in CRSwNP or asthma trials, as reported in Rhinology 2020 6

Regulatory Status

• The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 recommends dupilumab for treatment of CRSwNP meeting criteria for biologic therapy 6

Dupilumab Candidacy and Safety in Type 2 Inflammatory Diseases

Indications and Candidate Criteria

• Dupilumab is recommended for patients with moderate‑to‑severe disease who have failed ≥ 4 weeks of optimized intranasal corticosteroids (for chronic rhinosinusitis with nasal polyps), optimized topical therapy (for atopic dermatitis), or remain uncontrolled on inhaled corticosteroids (for asthma), with a preference for those demonstrating type 2 inflammatory markers (American Academy of Dermatology guideline) 8.

• In atopic dermatitis, a moderate‑to‑severe phenotype is defined by an Investigator’s Global Assessment score of ≥ 3 on a 0‑4 scale (American Academy of Dermatology guideline) 8.

• Patients whose atopic dermatitis is not adequately controlled with prescription topical therapies (topical corticosteroids and/or topical calcineurin inhibitors) meet criteria for dupilumab initiation (American Academy of Dermatology guideline) 8.

• All guideline work‑group members surveyed consider dupilumab the first‑line systemic agent for atopic dermatitis (American Academy of Dermatology guideline) 8.

• For chronic rhinosinusitis with nasal polyps, severe disease is identified by a nasal polyp score ≥ 6 on a 0‑8 scale despite ≥ 4 weeks of optimized intranasal corticosteroids (Rhinology) 9.

Safety and Monitoring

• Conjunctivitis occurs infrequently in respiratory‑disease trials of dupilumab; clinicians should monitor for this adverse event (Rhinology) [9][10].

• Injection‑site reactions have been reported in dupilumab trials for chronic rhinosinusitis with nasal polyps (Rhinology) 9.

• Nasopharyngitis was observed more often in placebo‑treated participants than in dupilumab‑treated participants in chronic rhinosinusitis with nasal polyps trials (Rhinology) 9.